New drug strategy aims to shrink tumors before surgery, keep cancer away after
NCT ID NCT05206812
Summary
This study is testing a treatment plan for people with operable non-small cell lung cancer. Patients receive an immunotherapy drug (durvalumab) before surgery, followed by surgery, and then more durvalumab plus standard chemotherapy after surgery. The main goal is to see how much the pre-surgery drug shrinks the tumor and to learn if this combined approach helps control the cancer long-term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.